FOXP2 and prostate carcinoma: We therefore evaluated the expression of FOXP2 in prostate cancer by analyzing several datasets, including our in-house samples (primary prostate cancer tumors, n = 92; matched normal tissues, n = 23), the SU2C dataset (metastatic prostate cancer samples, n = 117) (Robinson et al., 2015) and the GTEx dataset (normal prostate tissues, n = 106).